Based on the VICORE PHARMA HOLDING AB stock forecast from 0 analysts, the average analyst target price for VICORE PHARMA HOLDING AB is not available over the next 12 months. VICORE PHARMA HOLDING AB’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of VICORE PHARMA HOLDING AB is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, VICORE PHARMA HOLDING AB’s stock price was EUR 0.66. VICORE PHARMA HOLDING AB’s stock price has changed by +5.99% over the past week, +6.50% over the past month and -48.83% over the last year.
No recent analyst target price found for VICORE PHARMA HOLDING AB
No recent average analyst rating found for VICORE PHARMA HOLDING AB
Company Overview VICORE PHARMA HOLDING AB
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. Vicore Pharma Holding AB (publ) has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden. Read Less
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the tr...Read More
Frequently Asked Questions About VICORE PHARMA HOLDING AB (6Y4:F) Stock
Stock Target Advisor's fundamental analysis for VICORE PHARMA HOLDING AB's stock is Bearish.
Unfortunately we do not have enough data on 6Y4:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6Y4:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 6Y4:F's stock to indicate if its overvalued.
The last closing price of 6Y4:F's stock was EUR 0.66.
The most recent market capitalization for 6Y4:F is EUR 0.16B.
Unfortunately we do not have enough analyst data on 6Y4:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains VICORE PHARMA HOLDING AB's stock.
As per our most recent records VICORE PHARMA HOLDING AB has 29 Employees.
VICORE PHARMA HOLDING AB's registered address is Kornhamnstorg 53, Stockholm, Sweden, 111 27.
You can get more information about it from VICORE PHARMA HOLDING AB's website at https://www.vicorepharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About VICORE PHARMA HOLDING AB (6Y4:F) Stock
Stock Target Advisor's fundamental analysis for VICORE PHARMA HOLDING AB's stock is Bearish.
Unfortunately we do not have enough data on 6Y4:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 6Y4:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 6Y4:F's stock to indicate if its overvalued.
The last closing price of 6Y4:F's stock was EUR 0.66.
The most recent market capitalization for 6Y4:F is EUR 0.16B.
Unfortunately we do not have enough analyst data on 6Y4:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains VICORE PHARMA HOLDING AB's stock.
As per our most recent records VICORE PHARMA HOLDING AB has 29 Employees.
VICORE PHARMA HOLDING AB's registered address is Kornhamnstorg 53, Stockholm, Sweden, 111 27.
You can get more information about it from VICORE PHARMA HOLDING AB's website at https://www.vicorepharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 6Y4:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
